Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

CP101 & Clostridioides difficile infection (CDI) (recurrent)

Navigation

Contents

Randomized clinical trials (RCTs)

NCT03110133
revealed that CP101 was more effective than a placebo in reducing Clostridioides difficile infection (CDI) (recurrent), and it maintained a safety profile comparable to the placebo.
Allegretti et al. 2025 Gastroenterology 168(2): 357-366

NCT05153499
No published results were found as of June 2026

Non-randomized clinical trials

NCT03497806
No published results found as of June 2026

see also:
Clostridioides difficile infection (CDI) (recurrent) & Drugs/Treatments
Microbiome-based therapeutics & Clostridioides difficile infection (CDI) (recurrent)

References (Sources)

First microbiome-based drug clears phase III, in clinical trial turnaround
Garber 2020 Nat. Rev. Drug Discov. 19: 655–656
Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial
Allegretti et al. 2025 Gastroenterology 168(2): 357-366

AI Chat

11/5/2026

Chat with our artificial intelligence: